The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease

Summary

E5555 is a potent protease-activated receptor (PAR-1) antagonist targeting the G-coupled receptor and modulating thrombinplatelet-endothelial interactions. The drug is currently being tested in phase II trials in patients with coronary artery disease (CAD) and has potential antithrombotic and anti-inflammatory benefits.We investigated the in-vitro effects of E5555 on platelet function beyond PAR-1 blockade in healthy volunteers and CAD patients treated with aspirin (ASA) with or without clopidogrel. Conventional aggregation induced by 5 µM ADP, 1 µg/ml collagen, 10 µM TRAP, whole blood aggregation with 1 µg/ml collagen, and expression of 14 intact, and TRAP-stimulated receptors by flow cytometry were utilised to assess platelet activity after preincubation with escalating concentrations of E5555 (20 ng/ml, 50 ng/ml, and 100 ng/ml) in healthy volunteers, CAD patients treated with ASA, and CAD patients treated with ASA and clopidogrel combination (n=10, for each group). E5555 inhibited a number of platelet biomarkers. Platelet inhibition was usually moderate, present already at 20 ng/ml, and was not seemingly dose-dependent without TRAP stimulation. E5555 caused 10–15% inhibition of ADP- and collagen-induced platelet aggregation in plasma, but not in whole blood.TRAP-induced aggregation was inhibited almost completely. PECAM-1, GP IIb/IIIa antigen, and activity with PAC-1, GPIb, thrombospondin, vitronectin receptor expression, and formation of platelet-monocyte aggregates were also significantly reduced by E5555.TRAP stimulation caused dose-dependent effects between 20 and 50 ng/ml E5555 doses. P-selectin, LAMP-1, LAMP, and CD40-ligand were not affected by E5555. In conclusion, E5555 in vitro moderately but significantly inhibits platelet activity beyond PAR-1 blockade. Antiplatelet potency of ASA alone, and the combination of ASA and clopidogrel may be enhanced by E5555 providing rationale for their synergistic use. Selective blockade of platelet receptors suggests unique antiplatelet properties of E5555 as a potential addition to current antithrombotic regimens.

Keywords

E5555 - PAR-1 - thrombin receptor antagonists - platelets - aspirin - clopidogrel - in vitro - coronary artery disease

• References

• 1 World Health Report. 2002. Reducing Risk, promoting healthy life. Geneva, Switzerland: World Health Organization.;
• 2 ISIS-2 Trial Investigators. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988; 02: 349-360.
• 3 Chen ZM, Jiang LX, Chen YP. et al. (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 366. 1607-1621.
• 4 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
• 5 Serebruany VL, Steinhubl SR, Berger PB. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
• 6 Lev EI, Patel RT, Maresh KJ. et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47: 27-33.
• 7 Dennington PM, Berndt MC. The thrombin receptor. Clin Exp Pharmacol Physiol 1994; 21: 349-358.
• 8 Macfarlane SR, Seatter MJ, Kanke T. et al. Proteinase-activated receptors. Pharmacol Rev 2001; 53: 245-282.
• 9 Vu T-KH, Hung DT, Wheaton VI. et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-1068.
• 10 Kahn ML, Nakanishi-Matsui M, Shapiro MJ. et al. Protease activated receptors 1 and 4 mediate activation of human platelets by thrombin. Clin Invest 1999; 103: 879-887.
• 11 Matsuoka T, Kogushi M, Kawata T. et al. Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury. Abstract.. JACC 2004; 43: 68A.
• 12 Kogushi M, Kobayashi H, Matsuoka T. et al. Antithrombotic and bleeding time effects of E5555, an orally active protease-activated receptor-1 antagonist, in guinea pigs. Abstract. Circulation 2003; 108 Suppl. IV 280.
• 13 Kogushi M, Yokohama H, Kitamura S. et al. Effects of E5555, a protease-activated receptor-1 antagonist, on the inflammatory markers in vitro. Presented at XXIst Congress of the International Society on Thrombosis and Haemostasis; Geneva, Switzerland: 2007. Abstarct PM-059.
• 14 Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol 1994; 31: 229-239.
• 15 Zeidan AM, Kouides PA, Tara MA. et al. Platelet function testing: state of the art. Expert Rev Cardiovasc Ther 2007; 05: 955-967.
• 16 Serebruany VL, Gurbel PA. The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P – selectin?. Thromb Haemost 1999; 81: 314-316.
• 17 Badimon L, Vilahur G. Coronary atherothrombotic disease: progress in antiplatelet therapy. Rev Esp Cardiol 2008; 61: 501-513.
• 18 Serebruany VL, Miller M, Pokov AN. et al. Statins Inhibit Platelet PAR-1 Thrombin Receptor in Patients with Metabolic Syndrome :The PAR-1 Inhibition by Statins (PARIS) Study. Am J Cardiol 2006; 97: 1332-1336.